GSK – $1B SiranBio Oligo Deal

Summary GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction. What Happened GSK agreed to pay SiranBio $55 million upfront for rights to SA030,…